**Name of Journal:** *World Journal of Gastrointestinal Endoscopy*

**Manuscript NO:** 41168

**Manuscript Type:** EDITORIAL

**Screening for colorectal cancer in patients with inflammatory bowel disease. Should we already perform chromoendoscopy in all our patients?**

Huguet JM et al. Chromoendoscopy in IBD

Jose María Huguet, Patricia Suárez, Luis Ferrer-Barceló, Isabel Iranzo, Javier Sempere

**Jose María Huguet**, **Patricia Suárez**, **Luis Ferrer-Barceló, Isabel Iranzo,** **Javier Sempere,** Digestive Disease Department, Hospital General Universitario de Valencia, Valencia 46014, Valencia, Spain

**ORCID number:** Jose María Huguet (0000-0001-6486-1262); Patricia Suárez (0000-0001-9306-8378); Luis Ferrer-Barceló (0000-0001-8372-1572); Isabel Iranzo (0000-0002-2236-5727); Javier Sempere (0000-0002-6893-2512).

**Author contributions:** Huguet JM, Suárez P, Ferrer-Barceló L, Iranzo I andSempere J conceived the study and drafted the manuscript. All authors contributed to and approved the final version of the manuscript.

**Conflict-of-interest statement:**The authors have no conflicts of interest to report.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited Manuscript

**Correspondence to: Jose María Huguet, PhD, Assistant Professor,** Digestive Disease Department, Hospital General Universitario de Valencia, Avenida Tres Cruces 2, Valencia 46014, Valencia, Spain. huguet\_jos@gva.es

**Telephone:** +34-60-6394982

**Fax:** +34-96-3131901

**Received:** July 5, 2018

**Peer-review started:** July 5, 2018

**First decision:** August 2, 2018

**Revised:** August 4, 2018

**Accepted:** October 10, 2018

**Article in press:**

**Published online:**

**Abstract**

Patients with inflammatory bowel disease (IBD) have a greater risk of colorectal cancer than the general population. Therefore, they are included in special programs for screening and follow-up. Chromoendoscopy, which has a high diagnostic yield in the detection of neoplasia, is generally the recommended endoscopy technique. However, this procedure does have some disadvantages (long examination time, need for optimal bowel preparation, specialist training), which increase its cost. How then can we overcome these barriers? First, it is necessary to make hospital managers and directors aware of the advantages of chromoendoscopy in patients with IBD. Second, at least 1 endoscopist per center should be a specialist in the technique. Third, we should train nursing staff in the preparation of the dye. And finally, each examination should be given the time it needs. Even though clinical practice guidelines do not yet recommend the use of virtual imaging techniques such as narrowband imaging, a recent study reported no differences between the two approaches for the detection of tumors. Therefore, we believe that all patients should undergo chromoendoscopy. Perhaps in the future in centers without access to dyes or where there is some other barrier to performance of the technique, at least narrow band imaging should be performed.

**Key words:** Colorectal Cancer; Chromoendoscopy; Narrowband imaging; Inflammatory bowel disease; Surveillance

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip**: Patients with inflammatory bowel disease are included in special programs for screening and follow-up of colorectal cancer. It is generally recommended that endoscopy be performed using chromoendoscopy, which has a high diagnostic yield for detection of the disease. However, chromoendoscopy does have a series of disadvantages. While some clinical practice guidelines do not yet recommend the use of virtual imaging techniques such as narrowband imaging, a recent study reported that there were no differences between the two approaches for detection of neoplastic lesions. Therefore, we consider that all patients should undergo chromoendoscopy.

Huguet JM, Suárez P, Ferrer-Barceló L, Iranzo I, Sempere J. Screening for Colorectal Cancer in Patients with Inflammatory Bowel Disease. Should we already perform Chromoendoscopy in all our Patients? *World J Gastrointest Endosc* 2018; In press

**INTRODUCTION**

Patients with inflammatory bowel disease (IBD) have a greater risk of colorectal cancer (CRC) than the general population[1]. Therefore, it is clear that these patients should be included in special programs for screening and follow-up, as attested to in the recommendations of scientific societies and a recent review by Huguet *et al*[2-4]. The general recommendation for endoscopy is that the procedure used should be chromoendoscopy[3-5]. Chromoendoscopy is an imaging technique that uses contrast agents to identify abnormalities in the colonic mucosa. Dysplastic lesions are better highlighted by the addition of topical dyes. Chromoendoscopy has the advantage of detect early lesion other than dysplasia associated lesion or mass[7]. Chromoendoscopy is usually performed with methylene blue 0.1% or indigo carmine 0.03% to 0.5%. Cecal intubation should be performed using a white-light endoscope. The colonic mucosa should then be stained by spray aspirating the excess fluids, carefully evaluating the mucosa, and examining each segment before applying dye in the next one[2].

**CHROMOENDOSCOPY *VS* WHITE LIGHT ENDOSCOPY *VS* NARROW BAND IMAGING**

Several studies have evaluated the superiority of chromoendoscopy with respect to white light endoscopy[8]. A recent review compared the diagnostic yield of high-definition white light endoscopy, chromoendoscopy, and narrow band imaging (NBI) for detection of cancer in patients with IBD by means of a meta-analysis of the existing literature[9]. The authors found that chromoendoscopy was superior to white light endoscopy for detection of dysplasia in IBD. No differences in diagnostic yield were demonstrated for NBI in comparison with other modalities[9].

Therefore, we have sufficient evidence to recommend implementation of this technique in digestive endoscopy units, as recently shown by Shukla *et al*[10].

The cost of chromoendoscopy is increased by its disadvantages. It is time-consuming, requires optimal bowel preparation, and is subject to adverse effects caused by application of dye to the intestinal mucosa. In addition, the endoscopist must be specially trained (Table 1). How then can we overcome these barriers? First, it is necessary to make hospital managers and directors aware of the advantages of chromoendoscopy in patients with IBD. Second, at least 1 endoscopist per center should be a specialist in the technique. Third, we should train nursing staff in the preparation of the dye. And finally, each examination should be given the time it needs.

These are some of the reasons why chromoendoscopy is not universally used for CRC screening in patients with IBD. A Japanese study found that only half of those surveyed used the technique[11]. The recommended alternative to chromoendoscopy is high-definition video-colonoscopy and serial colon biopsy (4 every 10 cm)[5], which is also somewhat time-consuming if the biopsy specimens are taken as appropriate every 10 cm. In addition, potentially malignant lesions observed during the procedure must be biopsied. Preparation must also be optimal to ensure high-quality imaging. However, the technique is not subject to the possible adverse effects of dyes and does not require special training.

Moussata *et al*[12] recently reported that in selected patients, chromoendoscopy should be accompanied by conventional biopsy. The authors conclude that despite their low yield, random biopsies should be performed in association with chromoendoscopy in patients with IBD and a personal history of cancer, concomitant primary sclerosing cholangitis, or a tubular colon during colonoscopy[12].

A study carried out in Spanish units with a special interest in chromoendoscopy evaluated the real-world effectiveness of the technique. The rate of non-detection of dysplasia with white light endoscopy was 40/94 (incremental yield of 57.4% for chromoendoscopy). The rate of detection of dysplasia was similar for both experts and nonexperts (18.5% *vs* 13.1%, *P* = 0.20). The authors conclude that chromoendoscopy has a high diagnostic yield for the detection of neoplasia, irrespective of the technology used and the experience available at a specific center. Furthermore, optical diagnosis of chromoendoscopy is very accurate for ruling out dysplasia, especially when the technique is performed by an expert[13].

Clinical practice guidelines do not yet recommend NBI-type virtual imaging techniques for endoscopy in CRC screening[3]. Similarly, the SCENIC Consensus Statement does not recommend their use, and in Statement 6, the recommendation is that when performing surveillance with image-enhanced high-definition colonoscopy, NBI is not suggested in place of chromoendoscopy[5]. A Spanish study published in 2011 compared NBI with chromoendoscopy for the detection of colitis-associated intraepithelial neoplasia. The study was prospective, randomized, and crossover in design, and patients underwent both chromoendoscopy and NBI in a random order. The authors concluded that NBI is a useful technique for the detection of dysplasia in patients with long-standing IBD that offers several advantages, namely, efficiency, ease of use, and speed. However, in NBI, a relatively high number of cases of intraepithelial neoplasia may go undetected, with the result that many patients could go undiagnosed. Therefore, the authors consider that chromoendoscopy should still be considered the technique of choice for detecting dysplasia in patients with long-standing IBD[14].

Nevertheless, recent evidence suggests that NBI-type techniques could be the same as chromoendoscopy for the detection of dysplasia and CRC. Thus, a recent clinical trial compared the yield of chromoendoscopy with that of virtual chromoendoscopy using NBI in patients with a long history of ulcerative colitis and found no differences between the two techniques for detection of tumors. The authors concluded that given the longer extraction time of chromoendoscopy and easier applicability of NBI, the latter could replace classic chromoendoscopy[15].

Autofluorescence imaging, on the other hand, has not shown any advantages over chromoendoscopy[16].

**CONCLUSION**

Finally, we concur with Shukla *et al*[10] on the need for more studies, particularly longitudinal studies to clarify the role of chromoendoscopy in achieving the objective of reducing morbidity and mortality among patients with colitis-associated CRC, while reducing the number of unnecessary colectomies in patients with clinically insignificant lesions. Similarly, we should stress the need for studies comparing chromoendoscopy and NBI: If both techniques are similarly effective for the detection of neoplasia, the previously mentioned advantages of NBI could lead it to replace chromoendoscopy.

Therefore, we believe that the answer to the question we ask in the title of this editorial - Should all patients still undergo chromoendoscopy? - Is yes: we should perform chromoendoscopy in all patients with IBD who are to be screened and followed up for CRC. Perhaps in the future in centers without access to dyes or where there is some other barrier to performance of the technique, at least NBI should be performed.

**REFERENCES**

1 **Moran CP**, Neary B, Doherty GA. Endoscopic evaluation in diagnosis and management of inflammatory bowel disease. *World J Gastrointest Endosc* 2016; **8**: 723-732 [PMID: 28042386 DOI: 10.4253/wjge.v8.i20.723]

2 **Huguet JM**, Suárez P, Ferrer-Barceló L, Ruiz L, Monzó A, Durá AB, Sempere J. Endoscopic recommendations for colorectal cancer screening and surveillance in patients with inflammatory bowel disease: Review of general recommendations. *World J Gastrointest Endosc* 2017; **9**: 255-262 [PMID: 28690768 DOI: 10.4253/wjge.v9.i6.255]

3 **Magro F**, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagórowicz E, Raine T, Harbord M, Rieder F; European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. *J Crohns Colitis* 2017; **11**: 649-670 [PMID: 28158501 DOI: 10.1093/ecco-jcc/jjx008]

4 **Centre for Clinical Practice at NICE (UK)**. Colonoscopic Surveillance for Prevention of Colorectal Cancer in People with Ulcerative Colitis, Crohn's Disease or Adenomas. 2011; [PMID: 22259825]

5 **Laine L**, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R; SCENIC Guideline Development Panel. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. *Gastroenterology* 2015; **148**: 639-651.e28 [PMID: 25702852 DOI: 10.1053/j.gastro.2015.01.031]

6 **American Society for Gastrointestinal Endoscopy Standards of Practice Committee.**, Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, Evans JA, Fanelli RD, Fisher DA, Fonkalsrud L, Foley K, Hwang JH, Jue TL, Khashab MA, Muthusamy VR, Pasha SF, Saltzman JR, Sharaf R, Cash BD, DeWitt JM. The role of endoscopy in inflammatory bowel disease. *Gastrointest Endosc* 2015; **81**: 1101-21.e1-13 [PMID: 25800660 DOI: 10.1016/j.gie.2014.10.030]

7 **Goran L**, Negreanu L, Negreanu AM. Role of new endoscopic techniques in inflammatory bowel disease management: Has the change come? *World J Gastroenterol* 2017; **23**: 4324-4329 [PMID: 28706415 DOI: 10.3748/wjg.v23.i24.4324]

8 **Bessissow T**, Dulai PS, Restellini S, Landry T, Bisschops R, Murad MH, Singh S. Comparison of Endoscopic Dysplasia Detection Techniques in Patients With Ulcerative Colitis: A Systematic Review and Network Meta-analysis. *Inflamm Bowel Dis* 2018; [PMID: 29846600 DOI: 10.1093/ibd/izy188]

9 **Har-Noy O**, Katz L, Avni T, Battat R, Bessissow T, Yung DE, Engel T, Koulaouzidis A, Eliakim R, Ben-Horin S, Kopylov U. Chromoendoscopy, Narrow-Band Imaging or White Light Endoscopy for Neoplasia Detection in Inflammatory Bowel Diseases. *Dig Dis Sci* 2017; **62**: 2982-2990 [PMID: 28965228 DOI: 10.1007/s10620-017-4772-y]

10 **Shukla R**, Salem M, Hou JK. Use and barriers to chromoendoscopy for dysplasia surveillance in inflammatory bowel disease. *World J Gastrointest Endosc* 2017; **9**: 359-367 [PMID: 28874956 DOI: 10.4253/wjge.v9.i8.359]

11 **Shinozaki M**, Kobayashi K, Kunisaki R, Hisamatsu T, Naganuma M, Takahashi KI, Iwao Y, Suzuki Y, Watanabe M, Itabashi M, Torii A, Takazoe M, Sugita A. Surveillance for dysplasia in patients with ulcerative colitis: Discrepancy between guidelines and practice. *Dig Endosc* 2017; **29**: 584-593 [PMID: 28066941 DOI: 10.1111/den.12803]

12 **Moussata D**, Allez M, Cazals-Hatem D, Treton X, Laharie D, Reimund JM, Bertheau P, Bourreille A, Lavergne-Slove A, Brixi H, Branche J, Gornet JM, Stefanescu C, Moreau J, Marteau P, Pelletier AL, Carbonnel F, Seksik P, Simon M, Fléjou JF, Colombel JF, Charlois AL, Roblin X, Nancey S, Bouhnik Y, Berger F, Flourié B; the GETAID. Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy? *Gut* 2018; **67**: 616-624 [PMID: 28115492 DOI: 10.1136/gutjnl-2016-311892]

13 **Carballal S**, Maisterra S, López-Serrano A, Gimeno-García AZ, Vera MI, Marín-Garbriel JC, Díaz-Tasende J, Márquez L, Álvarez MA, Hernández L, De Castro L, Gordillo J, Puig I, Vega P, Bustamante-Balén M, Acevedo J, Peñas B, López-Cerón M, Ricart E, Cuatrecasas M, Jimeno M, Pellisé M; EndoCAR group of the Spanish Gastroenterological Association and Spanish Digestive Endoscopy Society. Real-life chromoendoscopy for neoplasia detection and characterisation in long-standing IBD. *Gut* 2018; **67**: 70-78 [PMID: 27612488 DOI: 10.1136/gutjnl-2016-312332]

14 **Pellisé M**, López-Cerón M, Rodríguez de Miguel C, Jimeno M, Zabalza M, Ricart E, Aceituno M, Fernández-Esparrach G, Ginès A, Sendino O, Cuatrecasas M, Llach J, Panés J. Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. *Gastrointest Endosc* 2011; **74**: 840-848 [PMID: 21802681 DOI: 10.1016/j.gie.2011.05.013]

15 **Bisschops R**, Bessissow T, Joseph JA, Baert F, Ferrante M, Ballet V, Willekens H, Demedts I, Geboes K, De Hertogh G, Vermeire S, Rutgeerts P, Van Assche G. Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial. *Gut* 2018; **67**: 1087-1094 [PMID: 28698230 DOI: 10.1136/gutjnl-2016-313213]

16 **Vleugels JLA**, Rutter MD, Ragunath K, Rees CJ, Ponsioen CY, Lahiff C, Ket SN, Wanders LK, Samuel S, Butt F, Kuiper T, Travis SPL, D'Haens G, Wang LM, van Eeden S, East JE, Dekker E. Chromoendoscopy versus autofluorescence imaging for neoplasia detection in patients with longstanding ulcerative colitis (FIND-UC): an international, multicentre, randomised controlled trial. *Lancet Gastroenterol Hepatol* 2018; **3**: 305-316 [PMID: 29567006 DOI: 10.1016/S2468-1253(18)30055-4]

17 **Marion JF**, Sands BE. The SCENIC consensus statement on surveillance and management of dysplasia in inflammatory bowel disease: praise and words of caution. *Gastroenterology* 2015; **148**: 462-467 [PMID: 25702851 DOI: 10.1053/j.gastro.2015.01.029]

**P-Reviewer:** Pesce A, Lee CL, Skok P, Slomiany BL **S-Editor:** Dou Y **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Spain

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Disadvantages of chromoendoscopy (Adapted from Marion J and Sands B[17])**

|  |
| --- |
| Operator barriers: |
| Training of fellows, gastroenterologists, nurses, and staff Unknown learning curve Identifying clinically relevant lesions  |
| Operational barriers: |
| Availability of dye, equipment Billing and reimbursement Time requirement Prep quality Confounding of findings by inflammation |
| Knowledge barriers  |
| Uncertain natural history of dysplasia detected by CE Uncertain implications of prior surveillance findings for management |